What are NCCN recommendations for treatment of early-stage favorable Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Combined modality is the treatment of choice in patients with early-stage cHL. The National Comprehensive Cancer Network (NCCN) guidelines give the ABVD (doxorubicin [Adriamycin]/bleomycin/vinblastine/dacarbazine) regimen a category 1 rating (ie, the recommendation is based on high-level evidence and uniform NCCN consensus that the intervention is appropriate), but also list an 8-week Stanford V regimen (doxorubicin, vinblastine, mechlorethamine [or cyclophosphamide], etoposide, vincristine, bleomycin, and prednisone) as an alternative. [4]

ABVD is administered in four cycles. However, two cycles are suggested in highly selected patients with very favorable disease characterized by the following [4] :

  • No bulky disease

  • No extralymphatic involvement

  • Fewer than three sites of disease

  • Erythrocyte sedimentation rate (ESR) < 30 mm/hr, or < 50 mm/hr in patients without B symptoms

The European Society for Medical Oncology (ESMO) guidelines recommend two to three cycles of ABVD followed by involved-site radiation therapy (ISRT). Alternatively, patients may undergo PET-CT scanning after two cycles of ABVD: PET-postive patients then receive two cycles of BEACOPPesc (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone in escalated dose) followed by 30Gy ISRT; PET-negative patients undergo one cycle of BEACOPPesc followed by 20Gy ISRT. [5]  

ESMO notes that whether RT can be omitted in selected patients with complete metabolic response at interim PET is a matter of debate. However, this approach may be offered to individual patients in whom the late risk of RT is thought to outweigh the short-term benefit of improved disease control. [5]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!